Yuanxin Xing

Yuanxin Xing

Auto-generated profile, based on publicly available information

Yuanxin Xing

Research Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, 250013 Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
ZFZhaotian Feng
Zhaotian Feng
MLMuhua Luan
Muhua Luan
WZWenshuai Zhu
Wenshuai Zhu
YXYuanxin Xing
Yuanxin Xing
XMXiaoli Ma
Xiaoli Ma
YJYanfei Jia
Yanfei Jia

1 January 2026 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
FJFubo Jing
Fubo Jing
BYBing Yan
Bing Yan
CLChunlan Liu
Chunlan Liu
WZWenshuai Zhu
Wenshuai Zhu
MLMuhua Luan
Muhua Luan
YJYanfei Jia
Yanfei Jia

24 July 2026 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
CCChenbin Cao
Chenbin Cao
HQHe Qi
He Qi
LXLu Xiang
Lu Xiang
WZWenshuai Zhu
Wenshuai Zhu
YSYuxuan Shi
Yuxuan Shi
YXYuanxin Xing
Yuanxin Xing
Background:Kidney renal clear cell carcinoma (KIRC) is the most common subtype of renal cell carcinoma, accounting for 75–80% of cases. Although Prohibitin 1 (PHB1) has been implicated in tumorigenesis, its role in KIRC remains unclear. This study aimed to investigate the expression, function, and underlying mechanisms of PHB1 in KIRC.Methods:PHB1 expression and clinical relevance were analyzed using the Cancer Genome Atlas database (TCGA), Gene Expression Omnibus database (GEO), and TIMER3.0 datasets. Single-cell RNA sequencing (scRNA-seq) data from 19 KIRC patients and normal kidney samples were used to assess cell-type-specific expression. Functional experiments, including CCK-8, EdU incorporation, colony formation, and Transwell assays, were performed to evaluate the effects of PHB1 on cell proliferation, migration, and invasion. A xenograft model was used to evaluate the effects of PHB1 in vivo. Western blotting and correlation analyses were conducted to assess the potential regulatory interplay between VHL, SKP2, PHB1, and p53.Results:PHB1 was significantly downregulated in KIRC tissues. Single-cell analysis showed reduced PHB1 expression in tumor-derived epithelial cells, fibroblasts, endothelial cells, and immune cells. Lower PHB1 levels were associated with poorer overall survival. PHB1 overexpression inhibited proliferation and migration, whereas knockdown promoted these effects. In vivo, PHB1 overexpression reduced tumor growth. Moreover, VHL knockout altered the protein levels of SKP2 and PHB1. Cellular manipulation of PHB1 moderately altered endogenous p53 protein expression. Based on TCGA data analysis, PHB1 expression showed a positive correlation with VHL and a negative correlation with SKP2.Conclusions:Collectively, PHB1 acts as a potential tumor suppressor in KIRC. Its expression pattern is associated with the VHL-SKP2 signaling axis, and the tumor-suppressive effects of PHB1 may be partially associated with the modulation of p53 expression. These findings suggest that PHB1 has the potential to serve as a reliable biomarker and therapeutic candidate for KIRC treatment.